BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 15, Issue 8
This Article
Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (6384)
All Articles published online
The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.
Item 
Count 
PDF655
HTML5250
Figures (1-3)251
Tables (1-3)228
 Sum=6384
Feb 28, 2009 (publication date) through Nov 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef
For: Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009; 15(8): 942-954 [PMID: 19248193 DOI: 10.3748/wjg.15.942]
URL: https://www.wjgnet.com/1007-9327/full/v15/i8/942.htm
Number Citing Articles
1
K. G. Parhofer, K. I. Birkeland, R. DeFronzo, S. Del Prato, A. Bhaumik, A. Ptaszynska. Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND). International Journal of Clinical Practice 2009; 64(2): 160 doi: 10.1111/j.1742-1241.2009.02246.x
2
Pushpjeet Kanwar, Kris V. Kowdley. The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. Clinics in Liver Disease 2016; 20(2): 225 doi: 10.1016/j.cld.2015.10.002
3
G. S. MASTERTON, J. N. PLEVRIS, P. C. HAYES. Review article: omega‐3 fatty acids – a promising novel therapy for non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2010; 31(7): 679 doi: 10.1111/j.1365-2036.2009.04230.x
4
Hisato Takagi, Takuya Umemoto. Telmisartan improves insulin sensitivity: A meta-analysis of randomized head-to-head trials. International Journal of Cardiology 2012; 156(1): 92 doi: 10.1016/j.ijcard.2011.11.070
5
Fiona J. Warner, Harinda Rajapaksha, Nicholas Shackel, Chandana B. Herath. ACE2: from protection of liver disease to propagation of COVID-19. Clinical Science 2020; 134(23): 3137 doi: 10.1042/CS20201268
6
Paschalis Paschos, Konstantinos Tziomalos. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World Journal of Hepatology 2012; 4(12): 327-331 doi: 10.4254/wjh.v4.i12.327
7
Nisha Sharma, Anannya Sircar, Hans-Joachim Anders, Anil Bhanudas Gaikwad. Crosstalk between kidney and liver in non-alcoholic fatty liver disease: mechanisms and therapeutic approaches. Archives of Physiology and Biochemistry 2022; 128(4): 1024 doi: 10.1080/13813455.2020.1745851
8
Ratree Sawangjit, Bunchai Chongmelaxme, Pochamana Phisalprapa, Surasak Saokaew, Ammarin Thakkinstian, Kris V. Kowdley, Nathorn Chaiyakunapruk. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD). Medicine 2016; 95(32): e4529 doi: 10.1097/MD.0000000000004529
9
Chieko Ejima, Haruna Kuroda, Sonoko Ishizaki. A novel diet‐induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis. Physiological Reports 2016; 4(21) doi: 10.14814/phy2.13016
10
Wei Zhang, Yi-Zhi Xu, Bo Liu, Rong Wu, Ying-Ying Yang, Xiao-Qiu Xiao, Xia Zhang. Pioglitazone Upregulates Angiotensin Converting Enzyme 2 Expression in Insulin-Sensitive Tissues in Rats with High-Fat Diet-Induced Nonalcoholic Steatohepatitis. The Scientific World Journal 2014; 2014: 1 doi: 10.1155/2014/603409
11
Meena B. Bansal, Naichaya Chamroonkul. Antifibrotics in liver disease: are we getting closer to clinical use?. Hepatology International 2019; 13(1): 25 doi: 10.1007/s12072-018-9897-3
12
Yating Li, Hong Xu, Wenrui Wu, Jianzhong Ye, Daiqiong Fang, Ding Shi, Lanjuan Li. Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Oncotarget 2018; 9(35): 24155 doi: 10.18632/oncotarget.23816
13
Tuyet A T Nguyen, Arun J Sanyal. Pathophysiology guided treatment of nonalcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 2012; 27(s2): 58 doi: 10.1111/j.1440-1746.2011.07018.x
14
Thomas Klein, Masato Fujii, Jan Sandel, Yuichiro Shibazaki, Kyoko Wakamatsu, Michael Mark, Hiroyuki Yoneyama. Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis. Medical Molecular Morphology 2014; 47(3): 137 doi: 10.1007/s00795-013-0053-9
15
Diana Barb, Paola Portillo-Sanchez, Kenneth Cusi. Pharmacological management of nonalcoholic fatty liver disease. Metabolism 2016; 65(8): 1183 doi: 10.1016/j.metabol.2016.04.004
16
Ma Ai Thanda Han, Osama Altayar, Shadi Hamdeh, Varun Takyar, Yaron Rotman, Ohad Etzion, Eric Lefebvre, Rifaat Safadi, Vlad Ratziu, Larry J. Prokop, Mohammad Hassan Murad, Mazen Noureddin. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2019; 17(4): 616 doi: 10.1016/j.cgh.2018.06.011
17
G. S. MASTERTON, J. N. PLEVRIS, P. C. HAYES. Review article: omega‐3 fatty acids – a promising novel therapy for non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2010; 31(7): 679 doi: 10.1111/j.1365-2036.2009.04230.x
18
C. Moctezuma-Velázquez. Current treatment for non-alcoholic fatty liver disease. Revista de Gastroenterología de México (English Edition) 2018; 83(2): 125 doi: 10.1016/j.rgmxen.2018.05.014
19
Hisato Takagi, Masao Niwa, Yusuke Mizuno, Shin-nosuke Goto, Takuya Umemoto. A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction. Hypertension Research 2013; 36(7): 627 doi: 10.1038/hr.2012.233
20
William Peverill, Lawrie Powell, Richard Skoien. Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation. International Journal of Molecular Sciences 2014; 15(5): 8591 doi: 10.3390/ijms15058591
21
Abdulrahman Ismaiel, Dan L. Dumitrascu. How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease. American Journal of Therapeutics 2023; 30(3): e242 doi: 10.1097/MJT.0000000000001174
22
Neel Malhotra, Melanie D Beaton. Management of non-alcoholic fatty liver disease in 2015. World Journal of Hepatology 2015; 7(30): 2962-2967 doi: 10.4254/wjh.v7.i30.2962
23
Keisuke Okamura, Tetsu Okuda, Yosuke Takamiya, Kazuyuki Shirai, Hidenori Urata. High Fib4 index in patients with suspected NASH is associated with elevation of chymase-dependent angiotensin II-forming activity in circulating mononuclear leucocytes. Heart and Vessels 2019; 34(9): 1559 doi: 10.1007/s00380-019-01391-4
24
Ángel Brea, Xavier Pintó, Juan F. Ascaso, Mariano Blasco, Ángel Díaz, Pedro González-Santos, Antonio Hernández-Mijares, Teresa Mantilla, Jesús Millán, Juan Pedro-Botet. Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del hígado graso no alcohólico. Clínica e Investigación en Arteriosclerosis 2017; 29(4): 185 doi: 10.1016/j.arteri.2016.06.002
25
Luciana M. A. Borém, João F. R. Neto, Igor V. Brandi, Deborah F Lelis, Sergio H. S. Santos. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertension Research 2018; 41(6): 394 doi: 10.1038/s41440-018-0040-6
26
Keith Pereira, Jason Salsamendi, Javier Casillas. The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. Journal of Clinical Imaging Science 2015; 5: 32 doi: 10.4103/2156-7514.157860
27
Brian Lam, Zobair M Younossi. Novel treatment strategies for patients with nonalcoholic fatty liver disease. Clinical Investigation 2011; 1(2): 229 doi: 10.4155/cli.10.24
28
Newaz Hossain, Pushpjeet Kanwar, Smruti R. Mohanty. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterology Research and Practice 2016; 2016: 1 doi: 10.1155/2016/7109270
29
J K Dyson, Q M Anstee, S McPherson. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterology 2014; 5(4): 277 doi: 10.1136/flgastro-2013-100404
30
Shinji Takai, Denan Jin. Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis. International Journal of Molecular Sciences 2020; 21(20): 7543 doi: 10.3390/ijms21207543
31
Qiu-Zan Zhang, Ying-Li Liu, Yan-Rong Wang, Li-Na Fu, Jing Zhang, Xiu-Ru Wang, Bang-Mao Wang. Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease. Experimental and Therapeutic Medicine 2017; 14(3): 2689 doi: 10.3892/etm.2017.4809
32
Dawn M. Torres, Frances J. Jones, Janet C. Shaw, Christopher D. Williams, John A. Ward, Stephen A. Harrison. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trial. Hepatology 2011; 54(5): 1631 doi: 10.1002/hep.24558
33
Samer Gawrieh, Naga Chalasani. Alcoholic and Non-Alcoholic Fatty Liver Disease. 2016; : 313 doi: 10.1007/978-3-319-20538-0_16
34
Erika Rabelo F Siqueira. A Review of Pharmacological Treatments of NASH. Gastroenterology & Hepatology: Open Access 2015; 2(5) doi: 10.15406/ghoa.2015.02.00058
35
W. Nseir, A. Shalata, A. Marmor, N. Assy. Mechanisms Linking Nonalcoholic Fatty Liver Disease with Coronary Artery Disease. Digestive Diseases and Sciences 2011; 56(12): 3439 doi: 10.1007/s10620-011-1767-y
36
Sevket Balta. Atherosclerosis and Non-Alcoholic Fatty Liver Disease. Angiology 2022; 73(8): 701 doi: 10.1177/00033197221091317
37
Giovanni Targher, Christopher D. Byrne. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nature Reviews Nephrology 2017; 13(5): 297 doi: 10.1038/nrneph.2017.16
38
Luciana Mendes Araújo Borém, Daniela Fernanda Freitas, Amanda Souto Machado, Alanna Fernandes Paraíso, Bruna Viana Caldas, João Felício Rodrigues Neto, Juliana Pinto Lima, André Luiz Sena Guimarães, Alfredo Maurício Batista de Paula, Sérgio Henrique Sousa Santos. Angiotensin II type 1 receptor (AT1) blockade by Telmisartan attenuates hepatic steatosis in high-fat fed mice reducing Resistin, TRL4, and Myd88 expression. Egyptian Liver Journal 2022; 12(1) doi: 10.1186/s43066-022-00216-w
39
Reem T. Atawia, Ahmed Esmat, Doaa A. Elsherbiny, Ebtehal El‐Demerdash. Telmisartan ameliorates carbon tetrachloride‐induced acute hepatotoxicity in rats. Environmental Toxicology 2017; 32(2): 359 doi: 10.1002/tox.22240
40
Nicholas W.S. Chew, Mark D. Muthiah, Arun J. Sanyal. Cardiovascular Endocrinology and Metabolism. 2023; : 137 doi: 10.1016/B978-0-323-99991-5.00003-6
41
Laura Marino, François R Jornayvaz. Endocrine causes of nonalcoholic fatty liver disease. World Journal of Gastroenterology 2015; 21(39): 11053-11076 doi: 10.3748/wjg.v21.i39.11053
42
Dana de Gracia Hahn, Amedine Duret, Jake P. Mann. An AGTR1 Variant Worsens Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome. American Journal of Gastroenterology 2019; 114(4): 556 doi: 10.14309/ajg.0000000000000193
43
Eric P. Stahl, Devinder S. Dhindsa, Suegene K. Lee, Pratik B. Sandesara, Naga P. Chalasani, Laurence S. Sperling. Nonalcoholic Fatty Liver Disease and the Heart. Journal of the American College of Cardiology 2019; 73(8): 948 doi: 10.1016/j.jacc.2018.11.050
44
Iman Alqarni, Yieldez A. Bassiouni, Amira M. Badr, Rehab A. Ali. Telmisartan and/or chlorogenic acid attenuates fructose-induced non-alcoholic fatty liver disease in rats: Implications of cross-talk between angiotensin, the sphingosine kinase/sphingoine-1-phosphate pathway, and TLR4 receptors. Biochemical Pharmacology 2019; 164: 252 doi: 10.1016/j.bcp.2019.04.018
45
Hideki Fujii, Norifumi Kawada. Inflammation and fibrogenesis in steatohepatitis. Journal of Gastroenterology 2012; 47(3): 215 doi: 10.1007/s00535-012-0527-x
46
Edward Lebovics, Jonah Rubin. Non‐alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do. Diabetes/Metabolism Research and Reviews 2011; 27(5): 419 doi: 10.1002/dmrr.1198
47
Carolina M. Perdomo, Nuria Garcia-Fernandez, Javier Escalada. Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?. Journal of Clinical Medicine 2021; 10(9): 2040 doi: 10.3390/jcm10092040
48
Sumio Watanabe, Etsuko Hashimoto, Kenichi Ikejima, Hirofumi Uto, Masafumi Ono, Yoshio Sumida, Masataka Seike, Yoshiyuki Takei, Tetsuo Takehara, Katsutoshi Tokushige, Atsushi Nakajima, Masashi Yoneda, Toshiji Saibara, Goshi Shiota, Isao Sakaida, Makoto Nakamuta, Toshihiko Mizuta, Hirohito Tsubouchi, Kentaro Sugano, Tooru Shimosegawa. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Journal of Gastroenterology 2015; 50(4): 364 doi: 10.1007/s00535-015-1050-7
49
Miguel Malespin, Ammar Nassri. Endocrine Diseases and the Liver. Clinics in Liver Disease 2019; 23(2): 233 doi: 10.1016/j.cld.2018.12.006
50
N. Suksomboon, N. Poolsup, T. Prasit. Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. Journal of Clinical Pharmacy and Therapeutics 2012; 37(3): 319 doi: 10.1111/j.1365-2710.2011.01295.x
51
Akinobu Takaki, Daisuke Uchida, Kazuhide Yamamoto. Reactive Oxygen Species in Biology and Human Health. 2016; : 349 doi: 10.1201/b20228-33
52
Shahinul Alam, Mushfiqul Abrar, Saiful Islam, Mohammad Kamal, Mohammad J Hasan, Md. Abdullah S Khan, Nooruddin Ahmad. Effect of telmisartan and vitamin E on liver histopathology with non‐alcoholic steatohepatitis: A randomized, open‐label, noninferiority trial. JGH Open 2020; 4(4): 663 doi: 10.1002/jgh3.12315
53
Toshiya Machida, Taku Obara, Makoto Miyazaki, Jun Inoue, Nariyasu Mano. Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease. Annals of Hepatology 2022; 27(4): 100699 doi: 10.1016/j.aohep.2022.100699
54
Amedeo Lonardo, Stefano Bellentani, Curtis K. Argo, Stefano Ballestri, Christopher D. Byrne, Stephen H. Caldwell, Helena Cortez-Pinto, Antonio Grieco, Mariana V. Machado, Luca Miele, Giovanni Targher. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Digestive and Liver Disease 2015; 47(12): 997 doi: 10.1016/j.dld.2015.08.004
55
Paul Manka, Amos Zeller, Wing-Kin Syn. Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. Drugs 2019; 79(9): 903 doi: 10.1007/s40265-019-01126-9
56
Amedeo Lonardo, Stephen H Caldwell, Paola Loria. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. Expert Review of Endocrinology & Metabolism 2010; 5(3): 403 doi: 10.1586/eem.10.5
57
Dimitrios Oikonomou, Georgios Georgiopoulos, Vassiliki Katsi, Chris Kourek, Constantinos Tsioufis, Alexendra Alexopoulou, Evaggelia Koutli, Dimitrios Tousoulis. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?. European Journal of Gastroenterology & Hepatology 2018; 30(9): 979 doi: 10.1097/MEG.0000000000001191
58
Masashi Yoneda. VII. The Evidence of Pharmacologic Treatment for NASH. Nihon Naika Gakkai Zasshi 2020; 109(1): 56 doi: 10.2169/naika.109.56
59
George B Goh, Mangesh R Pagadala, Jaividhya Dasarathy, Aynur Unalp‐Arida, Ruth Sargent, Carol Hawkins, Achuthan Sourianarayanane, Amer Khiyami, Lisa Yerian, Rish Pai, Arthur J McCullough, Srinivasan Dasarathy. Renin‐angiotensin system and fibrosis in non‐alcoholic fatty liver disease. Liver International 2015; 35(3): 979 doi: 10.1111/liv.12611
60
Peter Sun, Joanne Chang, Jie Zhang, Kristijan H. Kahler. Evolutionary cost analysis of valsartan initiation among patients with hypertension: a time series approach. Journal of Medical Economics 2012; 15(1): 8 doi: 10.3111/13696998.2011.626097
61
Hitoshi Yoshiji. The Liver in Systemic Diseases. 2016; : 149 doi: 10.1007/978-4-431-55790-6_8
62
Natasha McDonald, Jonathan Fallowfield. Clinical Dilemmas in Non‐Alcoholic Fatty Liver Disease. 2016; : 218 doi: 10.1002/9781118924938.ch25
63
Stuart McPherson, Nina Wilkinson, Dina Tiniakos, Jennifer Wilkinson, Alastair D. Burt, Elaine McColl, Deborah D. Stocken, Nick Steen, Jane Barnes, Nicola Goudie, Stephen Stewart, Yvonne Bury, Derek Mann, Quentin M. Anstee, Christopher P. Day, Vincent Wong. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. PLOS ONE 2017; 12(4): e0175717 doi: 10.1371/journal.pone.0175717
64
Simona Cernea, Avivit Cahn, Itamar Raz. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. Expert Review of Clinical Pharmacology 2017; 10(5): 535 doi: 10.1080/17512433.2017.1300059
65
Mohsen Arabi, Raheleh Alimoradzadeh, Alireza Makian, Seyed Javad Shariat Nabavi, Farshad Divsalar, Mitra Kazemi Jahromi. Non-alcoholic Steatohepatitis Diagnosis and Treatment Medical and Surgery, Based on Guideline Updates: A Mini Review. Journal of Health Reports and Technology 2022; 8(3) doi: 10.5812/jhrt-119454
66
Krzysztof Lukasz Kopec, David Burns. Nonalcoholic Fatty Liver Disease. Nutrition in Clinical Practice 2011; 26(5): 565 doi: 10.1177/0884533611419668
67
Jonathan Merola, AnnMarie Liapakis, David C. Mulligan, Peter S. Yoo. Non‐alcoholic fatty liver disease following liver transplantation: a clinical review. Clinical Transplantation 2015; 29(9): 728 doi: 10.1111/ctr.12585
68
G. Musso, M. Cassader, F. Rosina, R. Gambino. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012; 55(4): 885 doi: 10.1007/s00125-011-2446-4
69
Shahinul Alam, SKM Nazmul Hasan, Golam Mustafa, Mahabubul Alam, Mohammad Kamal, Nooruddin Ahmad. Effect of pentoxifylline on histological activity and fibrosis of nonalcoholic steatohepatitis patients: A one year randomized control trial. Journal of Translational Internal Medicine 2017; 5(3): 155 doi: 10.1515/jtim-2017-0021
70
Yoshihisa Takahashi, Keiichiro Sugimoto, Hiroshi Inui, Toshio Fukusato. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World Journal of Gastroenterology 2015; 21(13): 3777-3785 doi: 10.3748/wjg.v21.i13.3777
71
Mazen Noureddin, Manal F. Abdelmalek. ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD?. Hepatology 2022; 76(2): 295 doi: 10.1002/hep.32399
72
K. H. Williams, N. A. Shackel, M. D. Gorrell, S. V. McLennan, S. M. Twigg. Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo. Endocrine Reviews 2013; 34(1): 84 doi: 10.1210/er.2012-1009
73
S. Kaser, C. F. Ebenbichler, H. Tilg. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. International Journal of Clinical Practice 2010; 64(7): 968 doi: 10.1111/j.1742-1241.2009.02327.x
74
Beth A Davison, Christopher Edwards, Rohit Loomba, Stephen A Harrison, Gad Cotter, Naim Alkhouri, Gary G Koch, Howard C Dittrich. Noninvasive measure of treatment response in non‐alcoholic steatohepatitis: Insights from EMMINENCE and meta‐analysis. JGH Open 2021; 5(7): 740 doi: 10.1002/jgh3.12575
75
Briohny W. Smith, Leon A. Adams. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nature Reviews Endocrinology 2011; 7(8): 456 doi: 10.1038/nrendo.2011.72
76
Giulio Marchesini, Simona Moscatiello, Federica Agostini, Nicola Villanova, Davide Festi. Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opinion on Emerging Drugs 2011; 16(1): 121 doi: 10.1517/14728214.2011.531700
77
Bilal Hameed, Norah Terrault. Emerging Therapies for Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2016; 20(2): 365 doi: 10.1016/j.cld.2015.10.015
78
Marilena Durazzo, Paola Belci, Alessandro Collo, Enrica Grisoglio, Simona Bo. Focus on Therapeutic Strategies of Nonalcoholic Fatty Liver Disease. International Journal of Hepatology 2012; 2012: 1 doi: 10.1155/2012/464706
79
Fernando Bril, Kenneth Cusi. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Diabetes Care 2017; 40(3): 419 doi: 10.2337/dc16-1787
80
Sudeep Pushpakom, Ruwanthi Kolamunnage-Dona, Claire Taylor, Terry Foster, Catherine Spowart, Marta Garcia-Finana, Graham J Kemp, Thomas Jaki, Saye Khoo, Paula Williamson, Munir Pirmohamed. Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT. Efficacy and Mechanism Evaluation 2019; 6(6): 1 doi: 10.3310/eme06060
81
Jia Xiao, Rui Guo, Man Lung Fung, Emily C Liong, George L Tipoe. Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges. Hepatobiliary & Pancreatic Diseases International 2013; 12(2): 125 doi: 10.1016/S1499-3872(13)60021-1
82
Sang Hoon Park. Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Korean Journal of Medicine 2014; 86(4): 425 doi: 10.3904/kjm.2014.86.4.425
83
Yuta Miyaoka, Denan Jin, Keitaro Tashiro, Koji Komeda, Shinsuke Masubuchi, Fumitoshi Hirokawa, Michihiro Hayashi, Shinji Takai, Kazuhisa Uchiyama. Chymase inhibitor prevents the development and progression of non-alcoholic steatohepatitis in rats fed a high-fat and high-cholesterol diet. Journal of Pharmacological Sciences 2017; 134(3): 139 doi: 10.1016/j.jphs.2017.04.005
84
Matthew R. Golder, Jenny Liu, Jannik N. Andersen, Michail V. Shipitsin, Farrukh Vohidov, Hung V.-T. Nguyen, Deborah C. Ehrlich, Sung Jin Huh, Bhavatarini Vangamudi, Kyriakos D. Economides, Allison M. Neenan, James C. Ackley, Joelle Baddour, Sattanathan Paramasivan, Samantha W. Brady, Eric J. Held, Lawrence A. Reiter, Jennifer K. Saucier-Sawyer, Paul W. Kopesky, Donald E. Chickering, Peter Blume-Jensen, Jeremiah A. Johnson. Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs. Nature Biomedical Engineering 2018; 2(11): 822 doi: 10.1038/s41551-018-0279-x
85
J. K. Dowman, M. J. Armstrong, J. W. Tomlinson, P. N. Newsome. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 2011; 13(8): 692 doi: 10.1111/j.1463-1326.2011.01403.x
86
Ángel Brea, Xavier Pintó, Juan F. Ascaso, Mariano Blasco, Ángel Díaz, Pedro González-Santos, Antonio Hernández-Mijares, Teresa Mantilla, Jesús Millán, Juan Pedro-Botet. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease. Clínica e Investigación en Arteriosclerosis (English Edition) 2017; 29(4): 185 doi: 10.1016/j.artere.2017.07.001
87
Marwan S.M. Al-Nimer, Vian A.W. Esmail, O. Mohammad. Telmisartan improves the metabolic, hematological and inflammasome indices in non-alcoholic fatty liver infiltration: A pilot open-label placebo-controlled study. Electronic Journal of General Medicine 2019; 16(3): em142 doi: 10.29333/ejgm/104568
88
Peter P. Toth. Pleiotropic Effects of Angiotensin Receptor Blockers: Addressing Comorbidities by Optimizing Hypertension Therapy. The Journal of Clinical Hypertension 2011; 13(1): 42 doi: 10.1111/j.1751-7176.2010.00379.x
89
Jörn M. Schattenberg, Detlef Schuppan. Nonalcoholic steatohepatitis. Current Opinion in Lipidology 2011; 22(6): 479 doi: 10.1097/MOL.0b013e32834c7cfc
90
Abdulrahman Ismaiel, Dan L. Dumitraşcu. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review. Frontiers in Medicine 2019; 6 doi: 10.3389/fmed.2019.00202
91
Sanjaya K. Satapathy, Arun J Sanyal. Novel treatment modalities for nonalcoholic steatohepatitis. Trends in Endocrinology & Metabolism 2010; 21(11): 668 doi: 10.1016/j.tem.2010.08.003
92
Yuta Miyaoka, Denan Jin, Keitaro Tashiro, Shinsuke Masubuchi, Maiko Ozeki, Fumitoshi Hirokawa, Michihiro Hayashi, Shinji Takai, Kazuhisa Uchiyama. A novel hamster nonalcoholic steatohepatitis model induced by a high-fat and high-cholesterol diet. Experimental Animals 2018; 67(2): 239 doi: 10.1538/expanim.17-0126
93
C. Moctezuma-Velázquez. Tratamiento actual de la enfermedad por hígado graso no alcohólico. Revista de Gastroenterología de México 2018; 83(2): 125 doi: 10.1016/j.rgmx.2017.10.003
94
Mohammad Said Ramadan, Vincenzo Russo, Gerardo Nigro, Emanuele Durante-Mangoni, Rosa Zampino. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. Journal of Clinical Medicine 2021; 10(8): 1569 doi: 10.3390/jcm10081569
95
Alexandra Jichitu, Simona Bungau, Ana Maria Alexandra Stanescu, Cosmin Mihai Vesa, Mirela Marioara Toma, Cristiana Bustea, Stela Iurciuc, Marius Rus, Nicolae Bacalbasa, Camelia Cristina Diaconu. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics 2021; 11(4): 689 doi: 10.3390/diagnostics11040689
96
Quentin M. Anstee, Alessandro Mantovani, Herbert Tilg, Giovanni Targher. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nature Reviews Gastroenterology & Hepatology 2018; 15(7): 425 doi: 10.1038/s41575-018-0010-0
97
Edwyn O. Cruz-López, Dien Ye, Congqing Wu, Hong S. Lu, Estrellita Uijl, Katrina M. Mirabito Colafella, A.H. Jan Danser. Angiotensinogen Suppression: A New Tool to Treat Cardiovascular and Renal Disease. Hypertension 2022; 79(10): 2115 doi: 10.1161/HYPERTENSIONAHA.122.18731
98
Giovanni Musso, Roberto Gambino, Maurizio Cassader, Gianfranco Pagano. A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease. Hepatology 2010; 52(1): 79 doi: 10.1002/hep.23623
99
Mariko Hojo, Sumio Watanabe. Pharmacological therapy of nonalcoholic steatohepatitis. Hepatology Research 2011; 41(3): 209 doi: 10.1111/j.1872-034X.2011.00780.x
100
Juan P Arab, Roberto Candia, Rodrigo Zapata, Cristián Muñoz, Juan P Arancibia, Jaime Poniachik, Alejandro Soza, Francisco Fuster, Javier Brahm, Edgar Sanhueza, Jorge Contreras, M Carolina Cuellar, Marco Arrese, Arnoldo Riquelme. Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review. World Journal of Gastroenterology 2014; 20(34): 12182-12201 doi: 10.3748/wjg.v20.i34.12182
101
Yu Wu, Kun L. Ma, Yang Zhang, Yi Wen, Gui H. Wang, Ze B. Hu, Liang Liu, Jian Lu, Pei P. Chen, Xiong Z. Ruan, Bi C. Liu. Lipid disorder and intrahepatic renin–angiotensin system activation synergistically contribute to non‐alcoholic fatty liver disease. Liver International 2016; 36(10): 1525 doi: 10.1111/liv.13131
102
Alessandro Mantovani, Giovanni Targher, Christopher D. Byrne. Textbook of Diabetes. 2024; : 820 doi: 10.1002/9781119697473.ch57
103
Briohny W. Smith, Leon A. Adams. Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences 2011; 48(3): 97 doi: 10.3109/10408363.2011.596521
104
Amedeo Lonardo, Stefano Ballestri, Giovanni Targher, Paola Loria. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2015; 9(5): 629 doi: 10.1586/17474124.2015.965143
105
Yoshio Sumida, Masashi Yoneda. Current and future pharmacological therapies for NAFLD/NASH. Journal of Gastroenterology 2018; 53(3): 362 doi: 10.1007/s00535-017-1415-1
106
Yue Li, Feng Xiong, Wen Xu, Side Liu. Increased Serum Angiotensin II Is a Risk Factor of Nonalcoholic Fatty Liver Disease: A Prospective Pilot Study. Gastroenterology Research and Practice 2019; 2019: 1 doi: 10.1155/2019/5647161
107
Geun Joo Choi, Hyun Min Kim, Hyun Kang, Jaetaek Kim. Effects of telmisartan on fat distribution: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion 2016; 32(7): 1303 doi: 10.1185/03007995.2016.1171204
108
Sudeep P Pushpakom, Claire Taylor, Ruwanthi Kolamunnage-Dona, Catherine Spowart, Jiten Vora, Marta García-Fiñana, Graham J Kemp, John Whitehead, Thomas Jaki, Saye Khoo, Paula Williamson, Munir Pirmohamed. Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy. BMJ Open 2015; 5(10): e009566 doi: 10.1136/bmjopen-2015-009566
109
Alessandro Mantovani, Andrea Dalbeni. Treatments for NAFLD: State of Art. International Journal of Molecular Sciences 2021; 22(5): 2350 doi: 10.3390/ijms22052350
110
E. Matthew Morris, Justin A. Fletcher, John P. Thyfault, R. Scott Rector. The role of angiotensin II in nonalcoholic steatohepatitis. Molecular and Cellular Endocrinology 2013; 378(1-2): 29 doi: 10.1016/j.mce.2012.04.013
111
Yi-Zhi Xu, Xia Zhang, Le Wang, Feng Zhang, Qiu Qiu, Mei-Ling Liu, Gui-Rong Zhang, Xiao-Ling Wu. An Increased Circulating Angiotensin II Concentration is Associated with Hypoadiponectinemia and Postprandial Hyperglycemia in Men with Nonalcoholic Fatty Liver Disease. Internal Medicine 2013; 52(8): 855 doi: 10.2169/internalmedicine.52.8839
112
Ran Jin, Jennifer K. Frediani, Jeffery Holzberg, Miriam B. Vos. Role of PAI-1 in Pediatric Obesity and Nonalcoholic Fatty Liver Disease. Current Cardiovascular Risk Reports 2017; 11(3) doi: 10.1007/s12170-017-0536-7
113
S. Gitto, G. Vitale, E. Villa, P. Andreone. Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future. Gastroenterology Research and Practice 2015; 2015: 1 doi: 10.1155/2015/732870
114
In Cheol Yoon, Jong Ryeol Eun. Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology. Yeungnam University Journal of Medicine 2019; 36(2): 67 doi: 10.12701/yujm.2019.00171
115
Wah‐Kheong Chan, Soek‐Siam Tan, Siew‐Pheng Chan, Yeong‐Yeh Lee, Hoi‐Poh Tee, Sanjiv Mahadeva, Khean‐Lee Goh, Anis Safura Ramli, Feisul Mustapha, Nik Ritza Kosai, Raja Affendi Raja Ali. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction‐associated fatty liver disease. Journal of Gastroenterology and Hepatology 2022; 37(5): 795 doi: 10.1111/jgh.15787
116
Holger Cynis, Astrid Kehlen, Monique Haegele, Torsten Hoffmann, Ulrich Heiser, Masato Fujii, Yuichiro Shibazaki, Hiroyuki Yoneyama, Stephan Schilling, Hans‐Ulrich Demuth. Inhibition of Glutaminyl Cyclases alleviates CCL2‐mediated inflammation of non‐alcoholic fatty liver disease in mice. International Journal of Experimental Pathology 2013; 94(3): 217 doi: 10.1111/iep.12020
117
Yan Wang, Shun Qiao, De-Wu Han, Xin-Ren Rong, Yi-Xiao Wang, Jing-jing Xue, Jing Yang. Telmisartan Improves Insulin Resistance: A Meta-Analysis. American Journal of Therapeutics 2018; 25(6): e642 doi: 10.1097/MJT.0000000000000733
118
Masahiro Sogabe, Toshiya Okahisa, Takeshi Kurihara, Masanori Takehara, Kaizo Kagemoto, Jun Okazaki, Yoshifumi Kida, Akihiro Hirao, Hironori Tanaka, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Masahiko Nakasono, Tetsuji Takayama, Jonathan M. Peterson. Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome. PLOS ONE 2020; 15(8): e0238388 doi: 10.1371/journal.pone.0238388
119
Sumio Watanabe, Etsuko Hashimoto, Kenichi Ikejima, Hirofumi Uto, Masafumi Ono, Yoshio Sumida, Masataka Seike, Yoshiyuki Takei, Tetsuo Takehara, Katsutoshi Tokushige, Atsushi Nakajima, Masashi Yoneda, Toshiji Saibara, Goshi Shiota, Isao Sakaida, Makoto Nakamuta, Toshihiko Mizuta, Hirohito Tsubouchi, Kentaro Sugano, Tooru Shimosegawa. Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology Research 2015; 45(4): 363 doi: 10.1111/hepr.12511
120
Nesrine S. El-Mezayen, Wessam F. El-Hadidy, Wessam M. El-Refaie, Thanaa I. Shalaby, Mahmoud M. Khattab, Aiman S. El-Khatib. Oral vitamin-A-coupled valsartan nanomedicine: High hepatic stellate cell receptors accessibility and prolonged enterohepatic residence. Journal of Controlled Release 2018; 283: 32 doi: 10.1016/j.jconrel.2018.05.021
121
Mariana V. Machado, Sara Gonçalves, Fátima Carepa, João Coutinho, Adília Costa, Helena Cortez‐Pinto. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver International 2012; 32(2): 241 doi: 10.1111/j.1478-3231.2011.02623.x
122
Kevan Josloff, Jacob Beiriger, Adnan Khan, Richard J. Gawel, Richard S. Kirby, Aaron D. Kendrick, Abhinav K. Rao, Roy X. Wang, Michelle M. Schafer, Margaret E. Pearce, Kashyap Chauhan, Yash B. Shah, Gregary D. Marhefka, Dina Halegoua-DeMarzio. Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. Journal of Cardiovascular Development and Disease 2022; 9(12): 419 doi: 10.3390/jcdd9120419
123
John Richard, Ildiko Lingvay. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Review of Cardiovascular Therapy 2011; 9(3): 321 doi: 10.1586/erc.11.15
124
Hisato Takagi, Yusuke Mizuno, Shin-nosuke Goto, Takuya Umemoto. Overview of telmisartan for blood pressure reduction among angiotensin II receptor blockers: A meta-analysis of head-to-head randomized trials. International Journal of Cardiology 2013; 167(6): 3051 doi: 10.1016/j.ijcard.2012.11.086
125
Amedeo Lonardo, Stefano Bellentani, Vlad Ratziu, Paola Loria. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient – death of a dogma from analysis of therapeutic studies?. Expert Review of Gastroenterology & Hepatology 2011; 5(2): 279 doi: 10.1586/egh.11.19
126
Karl Nadolsky, Donna R. Cryer, Amy Articolo, Travis Fisher, Jennifer Schneider, Mary Rinella. Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey. Annals of Medicine 2023; 55(1) doi: 10.1080/07853890.2023.2211349
127
Hisato Takagi, Takuya Umemoto. Telmisartan reduces triglyceride levels over other angiotensin II receptor blockers: A meta-analysis of randomized head-to-head trials. International Journal of Cardiology 2012; 157(3): 403 doi: 10.1016/j.ijcard.2012.02.008
128
J K Dyson, Q M Anstee, S McPherson. Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. Postgraduate Medical Journal 2015; 91(1072): 92 doi: 10.1136/postgradmedj-2013-100404rep
129
Hisato Takagi, Takuya Umemoto. A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients. Journal of the American Society of Hypertension 2014; 8(8): 578 doi: 10.1016/j.jash.2014.05.006
130
Shinji Takai, Denan Jin. Pathophysiological Role of Chymase-Activated Matrix Metalloproteinase-9. Biomedicines 2022; 10(10): 2499 doi: 10.3390/biomedicines10102499
131
Thuy-Anh Le, Rohit Loomba. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. Journal of Clinical and Experimental Hepatology 2012; 2(2): 156 doi: 10.1016/S0973-6883(12)60104-2
132
Shinji Takai, Denan Jin. Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis. Frontiers in Pharmacology 2018; 9 doi: 10.3389/fphar.2018.00144
133
Dimitrios A. Koutoukidis, Elizabeth Morris, John A. Henry, Yusra Shammoon, Matthew Zimmerman, Moscho Michalopoulou, Susan A. Jebb, Paul Aveyard, Jee-Fu Huang. What proportion of people have a follow-up biopsy in randomized trials of treatments for non-alcoholic steatohepatitis?: A systematic review and meta-analysis. PLOS ONE 2021; 16(4): e0250385 doi: 10.1371/journal.pone.0250385
134
G. Musso, R. Gambino, M. Cassader. Non‐alcoholic fatty liver disease from pathogenesis to management: an update. Obesity Reviews 2010; 11(6): 430 doi: 10.1111/j.1467-789X.2009.00657.x
135
Yves Lacourcière. Telmisartan or Valsartan Alone or in Combination with Hydrochlorothiazide: A Review. Clinical and Experimental Hypertension 2013; 35(1): 50 doi: 10.3109/10641963.2012.690468
136
Nicholas W. S. Chew, Cheng Han Ng, Mark Dhinesh Muthiah, Arun J. Sanyal. Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease. Current Atherosclerosis Reports 2022; 24(7): 515 doi: 10.1007/s11883-022-01027-5
137
Josephine A. Grace, Chandana B. Herath, Kai Yan Mak, Louise M. Burrell, Peter W. Angus. Update on new aspects of the renin–angiotensin system in liver disease: clinical implications and new therapeutic options. Clinical Science 2012; 123(4): 225 doi: 10.1042/CS20120030
Write to the Help Desk
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345